SA
Go ProLog In
MAZE
OverviewIntelligenceChart

Analyst Sentiment

Wall St. Consensus
Buy
6 analysts·Limited coverage
75
Score
6 Buy (100%)0 Hold (0%)0 Sell (0%)
Rating Breakdown
Strong Buy
00%
Buy
6100%
Hold
00%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$46.00
+80.0%
Consensus
$57.50
+125.0%
Bull
$97.00
+279.5%
12-Month Target Range6 analysts
$46.00$57.50$97.00
Current $25.56Consensus
Current Price
$25.56
Upside to Consensus
$31.94

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev-30.50%
EPS—
FY2028
Rev-23.20%
EPS—
FY2029
Rev+377.58%
EPS—

Earnings Surprises

Recent Analyst Actions

Apr 14, 2026Truist Financial
Maze Therapeutics price target lowered to $64 from $68 at Truist
Target:$64.00
+133.4%from $27.42
Mar 17, 2026Truist Financial
Truist Securities Starts Maze Therapeutics (MAZE) at Buy
Target:$68.00
+34.9%from $50.39
Mar 10, 2026Mizuho Securities
Maze Therapeutics initiated with an Outperform at Mizuho
Target:$97.00
+90.0%from $51.06
Jan 19, 2026BTIG
Maze Therapeutics price target raised to $46 from $37 at BTIG
Target:$46.00
+12.8%from $40.77
Dec 19, 2025Guggenheim
Maze Therapeutics price target raised to $46 from $34 at Guggenheim
Target:$46.00
+9.7%from $41.91
Dec 4, 2025Wells Fargo
Maze Therapeutics initiated with an Overweight at Wells Fargo
Target:$55.00
+32.6%from $41.49
Dec 3, 2025H.C. Wainwright
Maze Therapeutics price target raised to $60 from $50 at H.C. Wainwright
Target:$60.00
+54.9%from $38.74
Nov 13, 2025Raymond James
Maze Therapeutics initiated with a Strong Buy at Raymond James
Target:$48.00
+50.8%from $31.84
Sep 15, 2025Guggenheim
Maze Therapeutics price target raised to $34 from $19 at Guggenheim
Target:$34.00
+46.2%from $23.25
Sep 2, 2025BTIG
Maze Therapeutics initiated with a Buy at BTIG
Target:$30.00
+95.8%from $15.32
Jul 8, 2025Wedbush
Wedbush bullish on Maze Therapeutics, initiates with an Outperform
Target:$17.00
+27.7%from $13.31

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance